Biohaven Pharmaceutical Hld

Biohaven Ltd. operates as a biopharmaceutical company that focuses on neurological and neuropsychiatric diseases. Its portfolio includes treatments for medical needs including focal epilepsy, obsessive compulsive disorder, spinocerebellar ataxia and spinal muscular atrophy. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Today, we take an in-depth look at Biohaven Pharmaceutical, a CNS concern with multiple 'shots on goal'.

Biohaven Pharmaceutical: An Intriguing CNS Play

Biohaven Pharmaceutical (BHVN)'s plans for a secondary offering of $300 million has given both shareholders and speculators a headache.

Biohaven Offering Seems to Make Sale Less Likely

Acer Therapeutics

Celgene

Intra-Cellular Therapies

Karyopharm Therapeutics

Merck

The FDA went overdrive in the month of June, deciding on several regulatory applications before the July 4 holiday.

Attention Biotech Investors: Mark Your Calendar For These July 2019 PDUFA Dates

Carnival

Liberty Latin America Ltd.

Liberty Latin America

Odonate Therapeutics

TG Therapeutics

According to GuruFocus Insider Data, these are the largest CEO buys during the past week.

Weekly CEO Buys Highlight (June 30)

CEO of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Vlad Coric bought 5,000 shares of BHVN on 06/26/2019 at an average price of $40.22 a share.

Biohaven Pharmaceutical Holding Co Ltd (BHVN) CEO Vlad Coric Bought $201,100 of Shares

Blue Apron

GCP Applied Technologies

These stocks missed out on a big Wall Street rally.

Why Blue Apron Holdings, Biohaven Pharmaceutical Holding, and GCP Applied Technologies Slumped Today

Dilution is coming for shareholders, while an acquisition doesn't seem as likely.

Here's Why Biohaven Pharmaceutical Plummeted Today

Calithera Biosciences

Eiger BioPharmaceuticals

Rockwell Medical

Tuesday was a breakout day for a few biotech companies, and that was the case even before news broke that the U.S. and China would be meeting at the G20 meeting in Japan.

Tuesday’s Top BioPharma Movers Deviating from the Market

AstraZeneca

Biogen

Johnson & Johnson

Eli Lilly

Roche Holding AG

Alzheimer's treatment continues to confound biotech companies in the wake of Biogen and Eisai's decision to terminate two late-stage tests. But scientists say there's hope in new theories.

Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures

Investors need to pay close attention to Biohaven Pharmaceutical (BHVN) stock based on the movements in the options market lately.

Implied Volatility Surging for Biohaven Pharmaceutical (BHVN) Stock Options

Rumor has it that the drugmaker is up for sale.

Here's Why Biohaven Pharmaceutical Jumped 20% Today

News for Biohaven Pharmaceutical Hld Stock (BHVN)